Your browser doesn't support javascript.
loading
ClearColi as a platform for untagged pneumococcal surface protein A production: cultivation strategy, bioreactor culture, and purification.
Cardoso, Valdemir M; Paredes, Sheyla A H; Campani, Gilson; Gonçalves, Viviane M; Zangirolami, Teresa C.
Affiliation
  • Cardoso VM; Graduate Program of Chemical Engineering (PPGEQ), Department of Chemical Engineering, Federal University of São Carlos (UFSCar), Rodovia Washington Luís, km 235, São Carlos, SP, 13565-905, Brazil.
  • Paredes SAH; Graduate Program of Chemical Engineering (PPGEQ), Department of Chemical Engineering, Federal University of São Carlos (UFSCar), Rodovia Washington Luís, km 235, São Carlos, SP, 13565-905, Brazil.
  • Campani G; Graduate Program of Chemical Engineering (PPGEQ), Department of Chemical Engineering, Federal University of São Carlos (UFSCar), Rodovia Washington Luís, km 235, São Carlos, SP, 13565-905, Brazil.
  • Gonçalves VM; Department of Engineering, Federal University of Lavras, Lavras, MG, 37200-900, Brazil.
  • Zangirolami TC; Laboratory of Vaccine Development, Butantan Institute, Av. Vital Brasil 1500, São Paulo, SP, 05503-900, Brazil.
Appl Microbiol Biotechnol ; 106(3): 1011-1029, 2022 Feb.
Article in En | MEDLINE | ID: mdl-35024919
Several studies have searched for new antigens to produce pneumococcal vaccines that are more effective and could provide broader coverage, given the great number of serotypes causing pneumococcal diseases. One of the promising subunit vaccine candidates is untagged recombinant pneumococcal surface protein A (PspA4Pro), obtainable in high quantities using recombinant Escherichia coli as a microbial factory. However, lipopolysaccharides (LPS) present in E. coli cell extracts must be removed, in order to obtain the target protein at the required purity, which makes the downstream process more complex and expensive. Endotoxin-free E. coli strains, which synthesize a nontoxic mutant LPS, may offer a cost-effective alternative way to produce recombinant proteins for application as therapeutics. This paper presents an investigation of PspA4Pro production employing the endotoxin-free recombinant strain ClearColi® BL21(DE3) with different media (defined, auto-induction, and other complex media), temperatures (27, 32, and 37 °C), and inducers. In comparison to conventional E. coli cells in a defined medium, ClearColi presented similar PspA4Pro yields, with lower productivities. Complex medium formulations supplemented with salts favored PspA4Pro yields, titers, and ClearColi growth rates. Induction with isopropyl-ß-D-thiogalactopyranoside (0.5 mM) and lactose (2.5 g/L) together in a defined medium at 32 °C, which appeared to be a promising cultivation strategy, was reproduced in 5 L bioreactor culture, leading to a yield of 146.0 mg PspA4Pro/g dry cell weight. After purification, the cell extract generated from ClearColi led to 98% purity PspA4Pro, which maintained secondary structure and biological function. ClearColi is a potential host for industrial recombinant protein production. KEY POINTS: • ClearColi can produce as much PspA4Pro as conventional E. coli BL21(DE3) cells. • 10.5 g PspA4Pro produced in ClearColi bioreactor culture using a defined medium. • Functional PspA4Pro (98% of purity) was obtained in ClearColi bioreactor culture. Graphical abstract.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bioreactors / Escherichia coli Language: En Journal: Appl Microbiol Biotechnol Year: 2022 Document type: Article Affiliation country: Brazil Country of publication: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bioreactors / Escherichia coli Language: En Journal: Appl Microbiol Biotechnol Year: 2022 Document type: Article Affiliation country: Brazil Country of publication: Germany